(II) 黄素作为潜在的光化疗剂
Namisha Das1, Bidisha Bora1, Aarti Upadhyay2
1Department of Chemistry, Gauhati University, Guwahati 781014, Assam, India. tridibgoswami05@gmail.com.
Dalton transactions (Cambridge, England : 2003)
|January 23, 2024
概括
新的铜 (II) 黄化合物复合体显示出强大的光触发性细胞毒性对癌细胞. 这些化合物在可见光下产生反应性氧物种,在癌细胞中选择性诱导亡,对正常细胞的毒性最小.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 癌症生物学 癌症生物学
背景情况:
- 黄类是具有显著健康益处的天然多.
- 铜 (II) 复合物因其细胞毒性特性而受到探索.
- 光动力疗法提供了针对性的癌症治疗.
研究的目的:
- 合成和表征新的铜 (II) 黄化合物复合物.
- 评估它们在癌细胞中的体外光触发细胞毒性.
- 研究它们与DNA和蛋白质等生物分子的相互作用.
主要方法:
- 使用各种类黄和配体合成六种[Cu(L1)(L2)](ClO4) 复合物.
- 使用单晶X射线衍射和循环电压计进行表征.
- 在可见光下和黑暗中对A549,MCF-7癌细胞和HPL1D正常细胞进行体外细胞毒性测定.
主要成果:
- 成功合成和表征了六个Cu (II) 黄化合物复合物.
- 复合体对A549和MCF-7细胞表现出剂量依赖的光细胞毒性,暗中毒性较低.
- 已证明与人血清白蛋白 (HSA) 和小牛胸腺DNA (ct-DNA) 有显著的结合.
- 可见光暴露导致了反应性氧物种的产生和亡的诱导.
- 复合体6显示在A549细胞的线粒体中具有优越的局部化.
结论:
- 合成的铜 (II) 黄化合物复合物是对癌细胞有效的光细胞毒剂.
- 它们的机制涉及ROS生成和诱导亡,对癌细胞具有选择性.
- 这些复合体对开发新型光动力癌症疗法充满希望.
更多相关视频
07:12Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
Published on: July 17, 2020
6.3K
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
2.4K
相关概念视频
Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
